Navigation Links
ARIUS announces fourth quarter and year-end fiscal 2007 financial results
Date:1/29/2008

TORONTO, Jan. 29 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced its financial and operational results for the fourth quarter and fiscal year, ended November 30, 2007.

"Fiscal 2007 was a critical year in our development, highlighted by the significant advancement we made with the pre-IND programs for our lead drug candidates, our CD44 Cancer Stem Cell Program, our Trop-2 Signal Transduction Program, our CD59 Complement Inhibitor Program and our CD9 Cancer Stem Cell Program. The majority of our programs target cancer stem cells, an area that cancer researchers are particularly excited about as cancer stem cells have been implicated as the key cells responsible for the growth and spread of cancer," said Dr. David Young, President and CEO. "Building on this momentum, fiscal 2008 will be a pivotal year for us as we transition from a pre-clinical to a clinical company with the mission of moving one or more of our lead products into human clinical trials."

Program Updates:

CD44 Cancer Stem Cell Program

- Announced positive findings demonstrating no dose-limiting toxic

effects of ARIUS' lead therapeutic, ARH460-16-2, at doses up to

95 mg/kg in a dose-ranging pilot toxicology study in a non-human

primate model.

- Achieved significant and potent tumor growth inhibitory activity in

in vivo animal models of breast, prostate, liver, and AML cancers.

- Engaged the manufacturer Avid Bioservices to produce ARIUS' lead

anti-CD44 MAb under Current Good Manufacturing Practices ("cGMP") for

human clinical trials. Cell line producing the humanized anti-CD44

antibody was successfully transferred to Avid.

- Presented key data at AACR, ASCO, ASCO's Breast Cancer Symposium,

and AACR-EORTC.

- Met with FDA to discuss plans
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
2. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
3. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
4. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
5. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
6. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
7. ARIUS to present at Chinese Global Financial Forum
8. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
9. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
10. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
11. China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Amgen (NASDAQ: AMGN ) announced ... per share dividend for the third quarter of 2014. ... to all stockholders of record as of the close ... About Amgen Amgen is committed to unlocking the potential ... discovering, developing, manufacturing and delivering innovative human therapeutics. This ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 According to ... "Biological Drugs Market - Global Industry Analysis, Size, Share, ... biological drugs market is estimated at USD 161,056.5 million ... CAGR of 10.1% from 2014 to 2020, to reach ... , The biological drugs market is witnessing a significant ...
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... Microdosing or Phase 0 clinical testing has ... phase of the drug development process in the ... providers in preclinical testing and technology dependence is ... alliances, fuelling growth opportunities in this sector.(Logo: ...
... BASEL, Switzerland, Feb. 10 Syngenta today announced that ... Rice Research Institute (ARRI) of Anhui Academy of Agricultural ... conducting laboratory and field tests of novel gene functions ... optimization in key crops such as corn and soybean. ...
... CHAMPAIGN, Ill. By pushing carbon nanotubes close ... of Illinois have demonstrated a remarkable increase in ... what was previously thought possible., The researchers drove ... carries more electrons down more paths, similar to ...
Cached Biology Technology:Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 2Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 3Syngenta Enters Into Research Collaboration With Anhui Academy, China 2Syngenta Enters Into Research Collaboration With Anhui Academy, China 3Carbon nanotube avalanche process nearly doubles current 2
(Date:7/25/2014)... time, Spanish researchers have detected an unknown interaction between ... are introduced into a droplet of salt water and ... crystallisation to create biomineralogical biosaline 3D morphologically complex formations, ... bacteria are revived. The discovery was made by chance ... of the Astrobiology journal and may help ...
(Date:7/24/2014)... -- The Geneva Healthcare Suite, an innovative technology platform ... room wait times by an average of 92 minutes ... to a recent study published in the Academic Emergency ... suite to access data from incoming patients, implanted cardiac ... Geneva,s technology platform we have been able to quickly ...
(Date:7/24/2014)... A new study has identified two factors that ... increase the production of highly qualified physics teachers. ... to champion physics teacher education in combination with ... initiatives remain viable. Science, Technology, Engineering and Math ... and the study points the way for institutions ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Creating sustainable STEM teacher preparation programs 2
... Department of Cell Biology and Histology at the University of ... boosted by means of retinoids. It was thought that this ... , Vitamin A, also known as retinol, is ... and as carotene in vegetables that have a yellow-orange colour, ...
... identified a compound that interferes with the pathogenic effects ... development of a new treatment for the disease. , ... that now afflicts 30,000 Americans, with another 150,000 at ... strikes in midlife and causes uncontrolled movements, loss of ...
... Dentistry professor has developed a calcium phosphate-based supplement that ... strength and thickness without the side effects of many ... of Biomaterials and Biomimetics and of Implant Dentistry, presented ... for Dental Research annual meeting on March 9, 2006. ...
Cached Biology News:Retinol for combating leukemia cells 2Retinol for combating leukemia cells 3MIT research holds promise for Huntington's treatment 2New study reveals promising osteoporosis treatment 2
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... is an enhanced form of Tobacco Etch ... highly active, and significantly more stable than ... AcTEV Protease specifically recognizes a seven amino ... making it useful for removing affinity tags ...
... The Heraeus HERAcell is the ideal ... including development of ova or embryos at ... specifically designed to provide everything needed to ... , , Safe and stable incubation conditions ...
SP6 RNA Polymerase, 50 l, 20 U/l ,Cap Scribe Buffer, 100 l, 5x conc....
Biology Products: